- Home
- ZDAI vs KPRX Comparison
ZDAI vs KPRX Comparison
Compare ZDAI & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZDAI | KPRX |
|---|---|---|
| Founded | 2022 | 1998 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6M | 11.3M |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ZDAI | KPRX |
|---|---|---|
| Price | $1.58 | $2.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 7.6K | ★ 10.6K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.20 | $1.76 |
| 52 Week High | $11.48 | $2.95 |
Technical Indicators
Market Signals| Indicator | ZDAI | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.89 | 51.13 |
| Support Level | $1.55 | $2.44 |
| Resistance Level | $1.78 | $2.61 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 46.55 | 52.00 |
Price Performance
Historical ComparisonAbout ZDAI Primega Group Holdings Limited Ordinary Shares
DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.